Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash & Equivalents (2019 - 2026)

Atea Pharmaceuticals' Cash & Equivalents history spans 8 years, with the latest figure at $79.3 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 33.57% to $79.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Mar 2026, down 33.57% year-over-year, with the annual reading at $95.7 million for FY2025, 78.78% down from the prior year.
  • Cash & Equivalents came in at $79.3 million for Q1 2026, down from $95.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $705.5 million in Q1 2022 to a low of $77.3 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $176.4 million (2022), against an average of $263.2 million.
  • Year-over-year, Cash & Equivalents skyrocketed 244.48% in 2024 and then plummeted 83.72% in 2025.
  • Atea Pharmaceuticals' Cash & Equivalents stood at $188.5 million in 2022, then decreased by 23.69% to $143.8 million in 2023, then soared by 213.59% to $451.0 million in 2024, then tumbled by 78.78% to $95.7 million in 2025, then fell by 17.13% to $79.3 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Cash & Equivalents are $79.3 million (Q1 2026), $95.7 million (Q4 2025), and $77.3 million (Q3 2025).